beta-alanine has been researched along with Complication, Postoperative in 45 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 202 patients received dabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation." | 9.17 | Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. ( Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E, 2013) |
| "Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required." | 9.16 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)." | 8.89 | Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. ( Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB, 2013) |
| "Uninterrupted oral anticoagulant (OA) therapy with warfarin has become the standard of care at many centers performing catheter ablation of atrial fibrillation (AF)." | 7.79 | Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. ( Doppalapudi, H; Gunter, A; Kay, GN; Maddox, W; McElderry, HT; Osorio, J; Plumb, VJ; Yamada, T, 2013) |
| "In patients undergoing left atrial catheter ablation for AF or left atrial flutter, use of periprocedural dabigatran etexilate provides a safe and effective anticoagulation strategy compared to warfarin." | 7.79 | Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. ( Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP, 2013) |
| " This case report describes a patient with a St Jude aortic valve replacement who suffered valve thrombosis and an embolic stroke when anti-coagulated with the direct thrombin inhibitor dabigatran etexilate." | 7.78 | Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran. ( Astell, H; Stewart, RA; White, HD; Young, L, 2012) |
| "In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran." | 7.78 | A comparison of bleeding complications post-ablation between warfarin and dabigatran. ( Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K, 2012) |
| "To compare the efficacy, in the prevention of venous thromboembolism (VTE), and safety, of rivaroxaban and dabigatran relative to the common comparator enoxaparin." | 7.77 | An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. ( Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P, 2011) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 6.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "A total of 202 patients received dabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation." | 5.17 | Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. ( Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E, 2013) |
| "Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required." | 5.16 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding." | 5.14 | Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. ( Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S, 2010) |
| "Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)." | 4.89 | Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. ( Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB, 2013) |
| " The US Food and Drug Administration recently approved 2 new oral anticoagulants, dabigatran and rivaroxaban, for stroke prevention in patients with atrial fibrillation, and is currently reviewing a drug application for a third new oral anticoagulant, apixaban." | 4.89 | Novel oral anticoagulants: a review of new agents. ( Wanat, MA, 2013) |
| "The present systematic review was conducted to assess the efficacy and safety of apixaban versus other anticoagulants, for the prevention of venous thromboembolism (VTE) following total hip replacement (THR) and total knee replacement (TKR) surgery." | 4.88 | The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. ( Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A, 2012) |
| "Uninterrupted oral anticoagulant (OA) therapy with warfarin has become the standard of care at many centers performing catheter ablation of atrial fibrillation (AF)." | 3.79 | Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. ( Doppalapudi, H; Gunter, A; Kay, GN; Maddox, W; McElderry, HT; Osorio, J; Plumb, VJ; Yamada, T, 2013) |
| "In patients undergoing left atrial catheter ablation for AF or left atrial flutter, use of periprocedural dabigatran etexilate provides a safe and effective anticoagulation strategy compared to warfarin." | 3.79 | Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. ( Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP, 2013) |
| " This case report describes a patient with a St Jude aortic valve replacement who suffered valve thrombosis and an embolic stroke when anti-coagulated with the direct thrombin inhibitor dabigatran etexilate." | 3.78 | Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran. ( Astell, H; Stewart, RA; White, HD; Young, L, 2012) |
| "Three pivotal phase 3 trials have demonstrated that oral dabigatran etexilate showed similar safety and efficacy to enoxaparin 40 mg once daily (qd) for venous thromboembolism (VTE) prevention in patients undergoing total knee or hip replacement." | 3.78 | Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. ( Clemens, A; Dahl, OE; Eriksson, BI; Feuring, M; Friedman, RJ; Hantel, S; Huo, M; Noack, H, 2012) |
| "In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran." | 3.78 | A comparison of bleeding complications post-ablation between warfarin and dabigatran. ( Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K, 2012) |
| "To compare the efficacy, in the prevention of venous thromboembolism (VTE), and safety, of rivaroxaban and dabigatran relative to the common comparator enoxaparin." | 3.77 | An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. ( Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P, 2011) |
| "Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery." | 2.49 | The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. ( Aldin, ES; Greenberg, C; Rachidi, S; Sachs, B; Streiff, M; Zeidan, AM, 2013) |
| "Dabigatran has the advantage of providing rapid and steady anticoagulation without requiring laboratory monitoring." | 2.49 | Dabigatran: a primer for neurosurgeons. ( Fugate, JE; Lanzino, G; McBane, RD; Rabinstein, AA, 2013) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 2.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| " Orally administered dabigatran after discharge from hospital appears safe for venous thromboembolism prophylaxis after RALP." | 1.40 | Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation. ( Joutsi-Korhonen, L; Lassila, R; Pétas, A; Rannikko, AS; Säily, VM; Taari, K, 2014) |
| "Dabigatran has been granted authorisation by the FDA in non-valvular atrial fibrillation (RE-LY trial) while rivaroxaban is expecting approval in this same indication (ROCKET trial)." | 1.37 | [Pharmacologic heterogeneity of new anticoagulants]. ( Combe, S; Conard, J; Flaujac, C; Horellou, MH; Samamaa, MM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.44) | 18.7374 |
| 1990's | 1 (2.22) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 42 (93.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guijarro Merino, R | 1 |
| Villalobos Sánchez, A | 1 |
| Bassiouny, M | 1 |
| Saliba, W | 1 |
| Rickard, J | 1 |
| Shao, M | 1 |
| Sey, A | 1 |
| Diab, M | 1 |
| Martin, DO | 1 |
| Hussein, A | 1 |
| Khoury, M | 1 |
| Abi-Saleh, B | 1 |
| Alam, S | 1 |
| Sengupta, J | 1 |
| Borek, PP | 1 |
| Baranowski, B | 1 |
| Niebauer, M | 1 |
| Callahan, T | 1 |
| Varma, N | 1 |
| Chung, M | 1 |
| Tchou, PJ | 1 |
| Kanj, M | 1 |
| Dresing, T | 1 |
| Lindsay, BD | 1 |
| Wazni, O | 1 |
| Maddox, W | 1 |
| Kay, GN | 1 |
| Yamada, T | 1 |
| Osorio, J | 1 |
| Doppalapudi, H | 1 |
| Plumb, VJ | 1 |
| Gunter, A | 1 |
| McElderry, HT | 1 |
| McKenzie, JL | 1 |
| Douglas, G | 1 |
| Bazargan, A | 1 |
| Schmitt, AR | 1 |
| Zender, CA | 1 |
| Bordeaux, JS | 1 |
| Kaiser, DW | 1 |
| Streur, MM | 1 |
| Nagarakanti, R | 1 |
| Whalen, SP | 1 |
| Ellis, CR | 1 |
| Haines, DE | 1 |
| Mead-Salley, M | 1 |
| Salazar, M | 1 |
| Marchlinski, FE | 1 |
| Zado, E | 1 |
| Calkins, H | 1 |
| Yarmohammadi, H | 1 |
| Nademanee, K | 1 |
| Amnueypol, M | 1 |
| Skanes, AC | 1 |
| Saklani, P | 1 |
| Liew, A | 1 |
| Douketis, J | 2 |
| Säily, VM | 1 |
| Pétas, A | 1 |
| Joutsi-Korhonen, L | 1 |
| Taari, K | 1 |
| Lassila, R | 1 |
| Rannikko, AS | 1 |
| Steinberg, BA | 1 |
| Hasselblad, V | 1 |
| Atwater, BD | 1 |
| Bahnson, TD | 1 |
| Washam, JB | 1 |
| Alexander, JH | 1 |
| Daubert, JP | 1 |
| Piccini, JP | 1 |
| Wanat, MA | 1 |
| Rachidi, S | 1 |
| Aldin, ES | 1 |
| Greenberg, C | 1 |
| Sachs, B | 1 |
| Streiff, M | 1 |
| Zeidan, AM | 1 |
| Herrmann, R | 1 |
| Thom, J | 1 |
| Wood, A | 1 |
| Phillips, M | 1 |
| Muhammad, S | 1 |
| Baker, R | 1 |
| Molinier, A | 1 |
| Acket, B | 1 |
| Bourrel, R | 1 |
| Lavezzi, O | 1 |
| Montastruc, JL | 1 |
| Bagheri, H | 1 |
| Capodanno, D | 1 |
| Angiolillo, DJ | 1 |
| Yau, JW | 1 |
| Liao, P | 1 |
| Fredenburgh, JC | 1 |
| Roberts, RS | 1 |
| Weitz, JI | 1 |
| Konturek, P | 1 |
| Hess, T | 1 |
| Winkle, RA | 1 |
| Mead, RH | 1 |
| Engel, G | 1 |
| Kong, MH | 1 |
| Patrawala, RA | 1 |
| Cui, J | 1 |
| Wu, B | 1 |
| Liu, C | 1 |
| Li, Z | 1 |
| Huisman, MV | 1 |
| Quinlan, DJ | 1 |
| Dahl, OE | 3 |
| Schulman, S | 1 |
| Loke, YK | 1 |
| Kwok, CS | 1 |
| Eriksson, BI | 2 |
| Huo, MH | 1 |
| Kurth, AA | 1 |
| Hantel, S | 2 |
| Hermansson, K | 1 |
| Schnee, JM | 1 |
| Friedman, RJ | 2 |
| Ganem, F | 1 |
| Serrano, CV | 1 |
| Fernandes, JL | 1 |
| Blotta, MH | 1 |
| Souza, JA | 1 |
| Nicolau, JC | 1 |
| Ramires, JA | 1 |
| Hueb, WA | 1 |
| Ageno, W | 1 |
| Prandoni, P | 1 |
| Lereun, C | 1 |
| Wells, P | 1 |
| Diamantopoulos, A | 1 |
| Rasul, F | 1 |
| Lees, M | 1 |
| Sengupta, N | 1 |
| Samama, CM | 1 |
| Matute, MC | 1 |
| Guillán, M | 1 |
| García-Caldentey, J | 1 |
| Buisan, J | 1 |
| Aparicio, M | 1 |
| Masjuan, J | 1 |
| Alonso de Leciñana, M | 1 |
| Dumont, B | 1 |
| Faille, D | 1 |
| Ajzenberg, N | 1 |
| Stewart, RA | 1 |
| Astell, H | 1 |
| Young, L | 1 |
| White, HD | 1 |
| Galanis, T | 1 |
| Kraft, WK | 1 |
| Merli, GJ | 1 |
| Van de Werf, F | 1 |
| Eikelboom, J | 2 |
| Samamaa, MM | 1 |
| Conard, J | 1 |
| Flaujac, C | 1 |
| Combe, S | 1 |
| Horellou, MH | 1 |
| Migliaccio-Walle, K | 1 |
| Rublee, D | 2 |
| Simon, TA | 2 |
| Alpert, JS | 1 |
| Cohen, A | 1 |
| Drost, P | 1 |
| Marchant, N | 1 |
| Mitchell, S | 1 |
| Orme, M | 1 |
| Sutton, A | 1 |
| Healey, JS | 1 |
| Wallentin, L | 1 |
| Oldgren, J | 1 |
| Yang, S | 1 |
| Themeles, E | 1 |
| Heidbuchel, H | 1 |
| Heidbuchle, H | 1 |
| Avezum, A | 1 |
| Reilly, P | 1 |
| Connolly, SJ | 1 |
| Yusuf, S | 1 |
| Ezekowitz, M | 1 |
| Fugate, JE | 1 |
| Rabinstein, AA | 1 |
| McBane, RD | 1 |
| Lanzino, G | 1 |
| McCullagh, L | 1 |
| Barry, M | 1 |
| Feuring, M | 1 |
| Clemens, A | 1 |
| Noack, H | 1 |
| Huo, M | 1 |
| Snipelisky, D | 1 |
| Kauffman, C | 1 |
| Prussak, K | 1 |
| Johns, G | 1 |
| Venkatachalam, K | 1 |
| Kusumoto, F | 1 |
| Aalbers, J | 1 |
| Tamura, M | 1 |
| Seki, M | 1 |
| Tsunezuka, Y | 1 |
| Tsubota, M | 1 |
| Sato, H | 1 |
| Nghiem, DD | 1 |
| Conrad, GR | 1 |
| Rezai, K | 1 |
| Kirchner, PT | 1 |
| Corry, RJ | 1 |
| Kuni, CC | 1 |
| du Cret, RP | 1 |
| Boudreau, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Comp[NCT00657150] | Phase 3 | 2,055 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants[NCT02185027] | 1,166 participants (Actual) | Observational | 2013-06-30 | Completed | |||
| Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600] | Phase 3 | 18,113 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All cause death, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 1 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 18 |
| Enoxaparin | 33 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 17 |
| Enoxaparin | 31 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 1 |
| Enoxaparin | 2 |
Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 4 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 60 |
| Enoxaparin | 67 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 61 |
| Enoxaparin | 69 |
Volume of blood loss for treated and operated patients during surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 404.9 |
| Enoxaparin | 411.0 |
Number of treated and operated patients with required blood transfusion on day of surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Transfusions required | Missing | |
| Dabigatran 220mg | 246 | 4 |
| Enoxaparin | 237 | 7 |
Frequency of patients with possible clinically significant abnormalities. (NCT00657150)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(964;962) | AST decrease N=(964;962) | ALT increase N=(966;962) | ALT decrease N=(966;962) | Bilirubin increase N=(966;962) | Bilirubin decrease N=(966;962) | |
| Dabigatran 220mg | 28 | 0 | 34 | 0 | 3 | 0 |
| Enoxaparin | 44 | 0 | 67 | 0 | 1 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major bleeding events | Major and clinically relevant bleeding events | Any bleeding events | |
| Dabigatran 220mg | 14 | 37 | 98 |
| Enoxaparin | 9 | 29 | 83 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00657150)
Timeframe: 3 months
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptomatic Deep Vein Thrombosis | symptomatic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 220mg | 2 | 0 | 1 | 1 | 0 |
| Enoxaparin | 4 | 1 | 0 | 2 | 1 |
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran 110 mg | 11 |
| Dabigatran 150 mg | 14 |
| Warfarin | 21 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 1.54 |
| Dabigatran 150 mg | 1.11 |
| Warfarin | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.85 |
| Dabigatran 150 mg | 4.32 |
| Warfarin | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.26 |
| Dabigatran 150 mg | 3.68 |
| Warfarin | 4.35 |
"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) | |
|---|---|---|
| Major bleeds | Minor bleeds | |
| Dabigatran 110 mg | 2.99 | 13.16 |
| Dabigatran 150 mg | 3.55 | 14.85 |
| Warfarin | 3.81 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage)] (Number) | |
|---|---|---|
| intracerebral hemorrhage | intracranial hemorrhage (ICH) | |
| Dabigatran 110 mg | 0.12 | 0.23 |
| Dabigatran 150 mg | 0.10 | 0.32 |
| Warfarin | 0.38 | 0.76 |
14 reviews available for beta-alanine and Complication, Postoperative
| Article | Year |
|---|---|
[Prophylaxis of venous thromboembolism in orthopedic surgery. Role of the new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2012 |
Perioperative management of anticoagulation in elective surgery.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Cardiovascular Di | 2013 |
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S | 2013 |
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2013 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzi | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2014 |
A systematic review and adjusted indirect comparison of oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Mor | 2014 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib | 2011 |
New anticoagulants: pharmacology and clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2011 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr | 2011 |
Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa | 2011 |
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta | 2012 |
Dabigatran: a primer for neurosurgeons.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Cerebral Hemorrhage; Dabigatran; Hum | 2013 |
4 trials available for beta-alanine and Complication, Postoperative
| Article | Year |
|---|---|
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Catheter Ablation; Comorb | 2013 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2010 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimida | 2011 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I | 2012 |
27 other studies available for beta-alanine and Complication, Postoperative
| Article | Year |
|---|---|
Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confidence Intervals; Dabig | 2013 |
Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2013 |
A new oral anticoagulant in the setting of dermatologic surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Derma | 2013 |
Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter A | 2013 |
Perioperative management of patients who are receiving a novel oral anticoagulant.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Perioperat | 2013 |
Dabigatran and mechanical valves: less effective and more risky than warfarin.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Prosthesis; Heart Valve Prosth | 2013 |
Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Laparoscopy; Mal | 2014 |
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2014 |
[Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Contraindications; Dabigatr | 2014 |
Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Catheter Obstruction; Catheters; Dabigatran; D | 2014 |
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles | 2014 |
Preoperative B-type natriuretic peptide, and not the inflammation status, predicts an adverse outcome for patients undergoing heart surgery.
Topics: Acrylamides; Aged; beta-Alanine; Biomarkers; Brazil; C-Reactive Protein; Cardiac Surgical Procedures | 2011 |
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigat | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2011 |
Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
Topics: Aged; Antithrombins; Aphasia; Benzimidazoles; beta-Alanine; Carotid Artery Diseases; Dabigatran; Fem | 2011 |
Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran.
Topics: Aortic Valve; Aortic Valve Stenosis; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Dr | 2012 |
Dabigatran for patients with a mechanical valve.
Topics: Benzimidazoles; beta-Alanine; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; I | 2012 |
[Pharmacologic heterogeneity of new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2011 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis | 2012 |
New directions in anticoagulation.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; | 2012 |
Prescribing trends for dabigatran etexilate in primary care.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabig | 2012 |
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; | 2012 |
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl | 2012 |
New ESC guidelines on atrial fibrillation accept reality of next generation of anti-coagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2012 |
[Treatment of mediastinal infection by continuous closed irrigation with an antibiotic solution in a new bone baby].
Topics: beta-Alanine; Drug Therapy, Combination; Female; Humans; Infant; Mediastinal Diseases; Postoperative | 1998 |
Diagnosis of pancreatic rejection with Tc-99m DTPA scintigraphy.
Topics: Alanine; beta-Alanine; Graft Rejection; Humans; Organometallic Compounds; Organotechnetium Compounds | 1989 |
Pancreas transplants: evaluation using perfusion scintigraphy.
Topics: Adult; Alanine; beta-Alanine; Female; Graft Rejection; Humans; Male; Middle Aged; Organometallic Com | 1989 |